The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine of Novartis. We collaborate across scientific and organizational boundaries, with a focus on powerful new technologies that have the potential to help produce therapeutic breakthroughs for patients.
Jay Bradner, M.D., is president of the Novartis Institutes for BioMedical Research. A physician-scientist, he focuses on discovery and early development of definitive therapies for serious diseases. Follow Jay: Twitter | LinkedIn
The research institutes of the NIBR network are located across the globe to gain access to the world's best scientific talent. This network of institutes maintains a highly collaborative culture that encourages teams and individuals to work across institutional and geographic boundaries.